Survodutide (BI 456906) GLP-1/Glucagon Dual Agonist
Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH).
Boehringer Ingelheim is advancing survodutide into three global Phase 3 trials in people living with overweight or obesity. A Phase 2 trial of survodutide in patients living with NASH is also ongoing. The NASH program has received Fast Track Designation from the U.S. FDA.
Survodutide is an investigational product and has not been approved by the U.S. Food & Drug Administration (“FDA”). The safety and effectiveness of survodutide has not been established.
Collaboration with Boehringer Ingelheim
Survodutide was co-invented by Zealand Pharma and Boehringer Ingelheim. Under the terms of the license and collaboration agreement, Boehringer Ingelheim is funding all research, development and commercialization activities related to survodutide. Zealand Pharma is eligible to receive certain milestone payments, plus high-single to low-double digit royalties on potential global sales by Boehringer Ingelheim.